Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2013

Sartorius Boosts PAT Portfolio with Advanced Biomass Sensor Technology

  • Sartorius Stedim Biotech (SSB) obtained exclusive global marketing and distribution rights to Aber Instruments’ single-use sensor technology for the biopharmaceutical market. Aber will supply SSB with measuring instruments. SSB will manufacture the biomass sensors under a license, integrate these into its single-use bioreactors, and exclusively market these products in a dual-branding arrangement. New single-use sensors will be developed by both companies.

    SSB has continuously expanded its process analytics portfolio over the past years in the area of single-use sensors to enable real-time, noninvasive measurement of critical process parameters such as pH, dissolved oxygen content, temperature, glucose, lactate, and biomass.

    “Single-use sensors make our disposable bags even more intelligent,” explained Stefan Schlack, senior vp of marketing at SSB. “They deliver real-time information about the progress of cell culture processes and help biopharmaceutical customers to understand their processes even better and further optimize them—a decisive competitive advantage.”

    In-line biomass sensors enable precise and reproducible information to be obtained on the progress of a fermentation process without having to take samples and analyze these in the laboratory, continued Schlack.

    “As a result, cells are not unnecessarily exposed to stress caused by manual sampling and contamination risks are eliminated. In conjunction with SSB’s existing PAT and software solutions, biomass sensors represent high-performance tools for modeling and optimizing biopharmaceutical development and manufacturing processes, as well as for further accelerating development times,” he noted.



Related content

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »